Download - Introduction to the FDASM
![Page 1: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/1.jpg)
Introduction to the FDASM
PF Anderson / Perplexity PeccableEmerging Technologies Librarian for the Health Sciences
University of Michigan
Monday, December 14, 2009
![Page 2: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/2.jpg)
What is #FDASM?
Monday, December 14, 2009
![Page 3: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/3.jpg)
Monday, December 14, 2009
![Page 4: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/4.jpg)
Main Questions Addressed
Monday, December 14, 2009
![Page 5: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/5.jpg)
Question Topics1. Accountability
2. Regulatory requirements best practices
3. Corrective information
4. Links
5. Adverse event reporting
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
Monday, December 14, 2009
![Page 6: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/6.jpg)
FDASM Resources
Monday, December 14, 2009
![Page 7: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/7.jpg)
Monday, December 14, 2009
![Page 8: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/8.jpg)
Monday, December 14, 2009
![Page 9: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/9.jpg)
Monday, December 14, 2009
![Page 10: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/10.jpg)
Monday, December 14, 2009
![Page 11: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/11.jpg)
Wordle from Transcripts
Monday, December 14, 2009
![Page 12: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/12.jpg)
Context: General
Monday, December 14, 2009
![Page 13: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/13.jpg)
Monday, December 14, 2009
![Page 14: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/14.jpg)
Monday, December 14, 2009
![Page 15: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/15.jpg)
Monday, December 14, 2009
![Page 16: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/16.jpg)
Context: Recent FDA Warning Letters
Monday, December 14, 2009
![Page 17: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/17.jpg)
Monday, December 14, 2009
![Page 18: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/18.jpg)
Monday, December 14, 2009
![Page 19: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/19.jpg)
Context: Social Media Use Examples
Monday, December 14, 2009
![Page 20: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/20.jpg)
Monday, December 14, 2009
![Page 21: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/21.jpg)
Monday, December 14, 2009
![Page 22: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/22.jpg)
Monday, December 14, 2009
![Page 23: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/23.jpg)
Monday, December 14, 2009
![Page 24: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/24.jpg)
Monday, December 14, 2009
![Page 25: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/25.jpg)
Monday, December 14, 2009
![Page 26: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/26.jpg)
Monday, December 14, 2009
![Page 27: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/27.jpg)
Context: European Precedents
Monday, December 14, 2009
![Page 28: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/28.jpg)
In 2003, Danish journalist Frede Damgaard published information on his website about Hyben Total, a product licensed in Denmark as a treatment for a wide range of conditions—including gout, kidney and bladder disorders, sciatica, diarrhea, and diabetes. The national regulator in 1999 refused it a marketing authorization. It is still sold as a medicine in Sweden and Norway. Mr. Damgaard’s positive description of Hyben Total’s effects on the symptoms of gout and arthritis led to his being prosecuted in the Danish courts on the grounds that it constituted advertising of a medicinal product whose sale was not authorized in Denmark, thus contravening Directive 2001/83/EC.
Monday, December 14, 2009
![Page 29: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/29.jpg)
Title VIII, Advertising, Article 86
1. For the purposes of this Title, ‘advertising of medicinal products’ shall include any form of door-to-door information, canvassing activity or inducement designed to promote the prescription, supply, sale or consumption of medicinal products; it shall include in particular:
- the advertising of medicinal products to the general public,
- advertising of medicinal products to persons qualified to prescribe or supply them,
- visits by medical sales representatives to persons qualified to prescribe medicinal products,
Monday, December 14, 2009
![Page 30: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/30.jpg)
Title VIII, Advertising, Article 86
- the supply of samples,
- the provision of inducements to prescribe or supply medicinal products by the gift, offer or promise of any benefit or bonus, whether in money or in kind, except when their intrinsic value is minimal,
- sponsorship of promotional meetings attended by persons qualified to prescribe or supply medicinal products,
- sponsorship of scientific congresses attended by persons qualified to prescribe or supply medicinal products and in particular payment of their travelling and accommodation expenses in connection therewith.
Monday, December 14, 2009
![Page 31: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/31.jpg)
Title VIII, Advertising, Article 86
2. The following are not covered by this Title:
- the labelling and the accompanying package leaflets, which are subject to the provisions of Title V,
- correspondence, possibly accompanied by material of a non-promotional nature, needed to answer a specific question about a particular medicinal product,
Monday, December 14, 2009
![Page 32: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/32.jpg)
Title VIII, Advertising, Article 86
- factual, informative announcements and reference material relating, for example, to pack changes, adverse-reaction warnings as part of general drug precautions, trade catalogues and price lists, provided they include no product claims,
- information relating to human health or diseases, provided that there is no reference, even indirect, to medicinal products.
Monday, December 14, 2009
![Page 33: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/33.jpg)
Monday, December 14, 2009
![Page 34: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/34.jpg)
Monday, December 14, 2009
![Page 35: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/35.jpg)
Context: Role of the Health Care Consumer
Monday, December 14, 2009
![Page 36: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/36.jpg)
To start and to put you in the right mood, you should know that this official meeting about
social media will take place in an office WITHOUT ANY CELL OR INTERNET ACCESS!
Monday, December 14, 2009
![Page 37: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/37.jpg)
DTC is direct-to-consumer
DTC is currently illegal in Europe
Monday, December 14, 2009
![Page 38: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/38.jpg)
Monday, December 14, 2009
![Page 39: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/39.jpg)
Monday, December 14, 2009
![Page 40: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/40.jpg)
More Questions: What are Yours?
Monday, December 14, 2009
![Page 41: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/41.jpg)
Monday, December 14, 2009
![Page 42: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/42.jpg)
Monday, December 14, 2009
![Page 43: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/43.jpg)
A Big One for Us
Does the FDA plan to proactively reach out to more stakeholders -- patients, public, and physicians in particular -- during the comment period? If so, how will it do that? What can we do to help?
Important!
Monday, December 14, 2009
![Page 44: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/44.jpg)
Main Questions Addressed
Monday, December 14, 2009
![Page 45: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/45.jpg)
1. Accountability
2. Regulatory requirements best practices
3. Corrective information
4. Links
5. Adverse event reporting
Monday, December 14, 2009
![Page 46: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/46.jpg)
1. For what online communications are manufacturers, packers, or distributors accountable?
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
Monday, December 14, 2009
![Page 47: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/47.jpg)
2. How can manufacturers, packers, or distributors fulfill regulatory requirements (e.g., fair balance, disclosure of indication and risk information, postmarketing submission requirements) in their Internet and social media promotion, particularly when using tools that are associated with space limitations and tools that allow for real-time communications (e.g., microblogs, mobile technology)?
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
Monday, December 14, 2009
![Page 48: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/48.jpg)
3. What parameters should apply to the posting of corrective information on Web sites controlled by third parties?
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
Monday, December 14, 2009
![Page 49: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/49.jpg)
4. When is the use of links appropriate?
5. Questions specific to Internet adverse event reporting
FROM: Federal Register Notice of Public Hearing: http://edocket.access.gpo.gov/2009/E9-22618.htm
Monday, December 14, 2009
![Page 50: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/50.jpg)
Things You Can Do NOW
Monday, December 14, 2009
![Page 51: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/51.jpg)
Survey: What Happens Now? Questions About the FDA’s Process for Creating Social Media Guidance: <http://www.surveymonkey.com/s.aspx?sm=cTTi_2bsVngf8aiRcggYywrg_3d_3d>
Monday, December 14, 2009
![Page 52: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/52.jpg)
Survey: Predicting the Future of the Drug Industry: 2010 and Beyond: <http://www.surveymonkey.com/s/3YJQ65B>
Monday, December 14, 2009
![Page 53: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/53.jpg)
Think about your concerns and hopes for the forthcoming guidelines. Register your comments.
Community discussion will be held in January to help with this
Monday, December 14, 2009
![Page 54: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/54.jpg)
Monday, December 14, 2009
![Page 55: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/55.jpg)
Monday, December 14, 2009
![Page 56: Introduction to the FDASM](https://reader034.vdocuments.net/reader034/viewer/2022042521/5400de7f8d7f72c4628b45a9/html5/thumbnails/56.jpg)
What do YOU want the FDA to do?
Monday, December 14, 2009